Our experimental results confirm the notion that upregulation of the PD-1/PD-L1 signaling pathway in tumor tissue, is a consequence of IFN-I activation and invasion by T cells, and predicts therapeutic benefit from therapeutic PD-1/PD-L1 blockade alone. The gene discussed is CD274; the disease is neoplasm.